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Introduction: Epithelial ovarian cancer (EOC) has one of the worst prognoses among gynecologic cancers. An
appropriate screening method is not available for EOC, and the initial symptoms such as abdominal pain or
bloating, anorexia, and urinary urgency are vague. As a result, most cases of EOC are diagnosed at an advanced
stage.
Case presentation: We report novel insights gained from the case of a 45-year-old, gravida 0, para 0 woman who
presented to the emergency department with complaints of general weakness, fatigue, and myalgia over the
previous two months. She reported progressive muscle weakness of the upper and lower extremities leading to
difficulty walking. Serum muscle enzymes, such as creatine phosphokinase, were markedly elevated. No evidence of
malignancy was detected upon imaging. A biopsy of the left vastus medialis muscle was performed, and the results
were consistent with primary myopathy with myofibrillar disarray, suggesting paraneoplastic necrotizing myopathy.
Explorative laparotomy was performed to evaluate these results, and histopathological analysis of the full specimen
revealed a grade 3 ovarian serous adenocarcinoma with direct invasion to the rectum.
Conclusions: Because of the lack of screening tools for EOC, any clinical findings suggesting its presence are
valuable, and the possibility of EOC should be considered in unknown primary malignancies with initial complaints
of muscle weakness or myalgia.
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Epithelial ovarian cancer (EOC) has the one of the worst
prognoses among gynecologic cancers [1,2]. No appro-
priate screening method is available for EOC, and the
initial symptoms are vague, including abdominal pain,
abdominal bloating, anorexia, and urinary urgency [3].
As a result, most cases of EOC are not diagnosed until
the disease has reached an advanced stage.
Often, cancers can present as paraneoplastic syn-
dromes, which are disorders associated with systemic
cancer and are caused by mechanisms other than direct
invasion or metastasis [4]. Among them, paraneoplastic
necrotizing myopathy (PNM) is a rare entity charac-
terized by a rapidly progressive, symmetric, painful,* Correspondence: jhblue5@naver.com
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unless otherwise stated.predominantly proximal muscle weakness leading to
severe disability [5]. PNM is mostly associated with pri-
mary cancers of the lung, breast, and gastrointestinal
tract [6-8], and until now, it has not been reported in
EOC. Notably, the myositides associated with EOC are
usually dermatomyositis or polymyositis [9,10], not
PNM.
We report a case of a patient with initial complaints of
muscle weakness and myalgia but none of the common
symptoms of ovarian cancer. After a thorough workup,
this patient was finally diagnosed with adenocarcinoma
of the ovary with multiple metastases.
Case presentation
A 45-year-old, gravida 0, para 0 woman presented to the
emergency department with complaints of general weak-
ness, fatigue, and myalgia over the previous two months.
She described a progressive muscle weakness of the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Biopsy of the left vastus medialis muscle. Some
degenerating and regenerating fibers are visible. Hematoxylin and
eosin staining, ×100.
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king. The patient had no history of diabetes mellitus,
alcoholism, toxin exposure, nutritional deficiency, or
medication use.
Upon physical examination, the only notable finding
was muscle weakness with a preserved gag reflex and no
lateralizing or extra-pyramidal signs. Laboratory studies
showed liver enzyme levels of aspartate transaminase and
alanine aminotransferase to be elevated to 283 and 318,
respectively. Serum levels of the muscle enzymes creatine
phosphokinase (CPK), lactate dehydrogenase (LDH),
myoglobin, and creatine kinase-MB (CK-MB) were mar-
kedly elevated (21311 IU/L, 3750 IU/L, 2707 ng/ml, andFigure 2 Abdominopelvic computed tomography (CT). Both ovaries ap198.9 ng/ml, respectively). The level of cancer antigen-125
was slightly elevated (59.5 U/ml), but other tumor markers
were within the normal ranges. In addition to the physical
examination and laboratory studies, we also performed a
nerve conduction study and electromyography, and the
patient’s muscle weakness was suggestive of a myopathy.
Examination of a biopsy specimen of the left vastus me-
dialis muscle showed findings consistent with those of
primary myopathy with myofibrillar disarray, suggesting
PNM (Figure 1).
In addition to examining the muscles, we also sought
imaging studies and located an unknown primary malig-
nancy. Chest computed tomography (CT) showed mild
interlobular septal thickening in both lungs, consistent
with pulmonary edema and passive, subsegmental atelec-
tasis in both lower lobes. Enlarged lymph nodes were
visible in the right hilum, left supraclavicular, and right
cardiophrenic areas, along with a small right pleural ef-
fusion. An abdominopelvic CT scan revealed scattered
seeding in the entire peritoneal cavity. Both ovaries ap-
peared normal, but the right ovary was slightly enlarged
(Figure 2). Pelvic magnetic resonance imaging (MRI)
showed two bilateral metastatic lymph nodes in the pel-
vic cavity and a 2 cm enhancing soft tissue nodule sug-
gestive of metastasis in the left perirectal space.
Based on the imaging suggesting the presence of a pri-
mary malignancy and the likely paraneoplastic myo-
pathy, explorative laparotomy was performed. The right
ovary was visualized as a 2 cm multicystic solid mass,
and the left ovary was 2.5 cm and normal in appearance.
Adenocarcinoma was found during frozen tissue exa-
mination of the right ovary, and we subsequently per-
formed staging surgery. Low anterior resection was alsopear normal, but the right ovary is slightly enlarged.
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cul-de-sac. No palpable nodules were observed on the
liver surface, spleen, stomach, or appendix.
After the laparotomy, histopathological analysis of the
entire specimen revealed a grade 3 ovarian serous
adenocarcinoma. The right ovary measured 2 × 1.8 cm,
and the left ovary measured 2.5 × 1.7 × 1.5 cm. Involve-
ment of the right ovarian surface and fallopian tube was
found, but the regional lymph nodes were spared. The
resected rectum revealed direct invasion of the serous
adenocarcinoma and metastases in 12 of 17 pericolic
lymph nodes. Postoperatively, the patient underwent
adjuvant chemotherapy with paclitaxel and carboplatin.
Muscle weakness improved, and CPK levels gradually
decreased.
Conclusions
Our report describes a patient who experienced muscle
weakness and myalgia as the initial presenting symptoms
of a primary ovarian malignancy. In this case, there was
no evidence of alternative causes of myopathy, such as
other malignancies or medications. To our knowledge,
this is the first report of PNM associated with EOC.
Malignancy-associated myopathy has been anecdotally
reported in the past, and among these reported myopa-
thies, idiopathic inflammatory myopathies (IIMs), mainly
dermatomyositis and polymyositis, were found to be asso-
ciated with cancer [5]. Specifically, the most common
histological type of IIM-related cancer is adenocarcinoma
[5]. According to a population-based study, dermato-
myositis is more strongly associated with ovarian cancer
patients than with the general population [11], but the
clinical correlation between cancer and inflammatory
myopathy can vary. A malignancy may occur before or in
parallel with the diagnosis of inflammatory myopathy.
Usually, cancer is found within three years of a myositis
diagnosis, but the risk of cancer is highest at the time of
diagnosis [5,11,12]. The relationship between cancer and
myositis was explained by humoral immunologic mecha-
nisms [12], and it is thought that the immune-mediated
destruction of muscle may be a type of paraneoplastic
manifestation of the immune system’s response to the
cancer.
One paraneoplastic syndrome, PNM, is characterized
by a symmetric and proximal myopathy accompanied by
increased levels of serum muscle enzymes such as crea-
tine kinase. Furthermore, nerve conduction studies and
electromyography findings in PNM are suggestive of my-
opathy. PNM is uniquely distinguishable from other
myositides such as dermatomyositis or polymyositis in
three ways. First, PNM is characterized by predominant
necrosis of muscle fibers with limited inflammation.
Additionally, glucocorticoids are the treatment of choice
in dermatomyositis, and PNM may not respond tocorticosteroid therapy. Lastly, although dermatomyositis
may have a clinical course independent of the cancer
treatment, the prognosis of PNM depends on the under-
lying malignancy. Consequently, the prognosis for PNM
is worse, with greater mortality [13]. Therefore, diag-
nosis of the underlying malignancy is critical to the
management of these patients. The successful treatment
of the malignancy is the mainstay of relieving the myo-
sitis symptoms.
In this study, we presented a case of ovarian serous
adenocarcinoma with concomitant PNM. Although never
reported until now, the possibility of EOC should be con-
sidered in unknown primary malignancies with initial
complaints of muscle weakness or myalgia.
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